Scarica l'app Stockscreener
4.98
8.26%
0.38
Dopo l'orario di chiusura:
4.97
-0.01
-0.20%
Aclarion Inc Borsa (ACON) Ultime notizie
Aclarion announces revised reverse stock split details - MSN
Aclarion (NASDAQ:ACON) Rating Increased to Hold at Wall Street Zen - Defense World
Aclarion, Inc. (NASDAQ:ACON) Sees Large Increase in Short Interest - Defense World
What margin trends mean for Aclarion Inc. stock2025 Risk Factors & High Conviction Buy Zone Picks - Улправда
Is Aclarion Inc. stock a smart buy before Fed meeting2025 Fundamental Recap & Reliable Breakout Forecasts - Улправда
Trading Action: Why Aclarion Inc. stock appeals to dividend seekersMarket Risk Report & Daily Growth Stock Investment Tips - Улправда
Is Aclarion Inc. stock cheap at current valuationPortfolio Value Summary & Growth-Oriented Investment Plans - Улправда
Retail Trends: Why Aclarion Inc. stock is seen as undervaluedShare Buyback & Community Consensus Picks - Улправда
Can Aclarion Inc. stock hit record highs again2025 Support & Resistance & Weekly Top Stock Performers List - Улправда
How Aclarion Inc. Equity Warrant stock benefits from global expansionGap Up & Long-Term Safe Investment Plans - Улправда
Will Aclarion Inc. Equity Warrant stock gain from strong economyEarnings Recap Summary & Community Trade Idea Sharing Platform - Улправда
Fund Flows: What margin trends mean for Aclarion Inc. stockMarket Performance Summary & Weekly Consistent Profit Watchlists - Улправда
Why Aclarion Inc. stock is seen as undervaluedPortfolio Risk Summary & High Conviction Buy Zone Alerts - Улправда
Is Aclarion Inc. Equity Warrant stock a safe haven asset2025 Investor Takeaways & Target Return Focused Stock Picks - DonanımHaber
Sell Signal: What margin trends mean for Aclarion Inc. stock2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Улправда
Why Aclarion Inc. stock appeals to dividend seekersJuly 2025 Pullbacks & Stepwise Entry and Exit Trade Signals - Улправда
Growth Value: What makes Aclarion Inc. (IT20) stock appealing to growth investorsWeekly Trade Review & Technical Analysis for Trade Confirmation - Улправда
Aclarion Earnings Notes - Trefis
Nasdaq Moves: Will ATLCP stock continue upward momentumWeekly Stock Summary & Daily Risk Controlled Trade Plans - moha.gov.vn
Ramsay Health Care (OTCMKTS:RMYHY) vs. Aclarion (NASDAQ:ACON) Financial Review - Defense World
What drives Aclarion Inc stock priceReal Estate Investment Trusts & These 3 Stocks Could Change Your Portfolio - earlytimes.in
Aclarion shares move higher after Nociscan highlighted in spine surgery journal - MSN
Aclarion announces publication of Nociscan article in pain issue of IJSS - MSN
Aclarion (ACON) Price Target Increased by 15.00% to 23.46 - Nasdaq
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) - Orthopedics This Week
Can Aclarion Inc. Equity Warrant stock maintain growth trajectory2025 Retail Activity & Free Real-Time Market Sentiment Alerts - Newser
Aclarion Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Will Aclarion Inc. stock deliver better than expected guidance2025 Performance Recap & AI Forecast Swing Trade Picks - Newser
Aclarion’s Nociscan featured in special pain issue of spine journal By Investing.com - Investing.com Nigeria
Is Aclarion Inc. (IT20) stock vulnerable to rate hikes2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
How Aclarion Inc. (IT20) stock gains from tech spendingMarket Performance Recap & Weekly Stock Performance Updates - Newser
Why Aclarion Inc. (IT20) stock stays resilientJuly 2025 Decliners & Target Return Focused Picks - Newser
How sustainable is Aclarion Inc. Equity Warrant stock dividend payout2025 Market Trends & Detailed Earnings Play Alerts - Newser
Aclarion, Inc. Stock (ACON) Opinions on Nociscan Technology Publication - Quiver Quantitative
Aclarion stock rises after feature in special pain issue of spine journal By Investing.com - Investing.com South Africa
Aclarion stock rises after feature in special pain issue of spine journal - Investing.com Canada
Aclarion’s Nociscan featured in special pain issue of spine journal - Investing.com
ACON FinancialsIncome Statement - Quiver Quantitative
Aclarion's Nociscan Featured in International Journal of Spine Surgery's Special Pain Issue, Highlighting Advances in Chronic Low Back Pain Diagnosis - Quiver Quantitative
Aclarion (Nasdaq: ACON) Nociscan case study guides targeted spine surgery - Stock Titan
Can Aclarion Inc. (IT20) stock sustain double digit ROEJuly 2025 Rallies & AI Powered Buy and Sell Recommendations - Newser
Is Aclarion Inc. (IT20) stock suitable for passive index fundsJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - Newser
Will Aclarion Inc. (IT20) stock sustain uptrend momentumQuarterly Trade Report & Smart Swing Trading Techniques - Newser
Will Aclarion Inc. stock remain a Wall Street favoriteIPO Watch & Target Return Focused Stock Picks - Newser
Aug Intraday: Will QRAFT AI Enhanced U.S. Large Cap stock return to pre crash levelsJuly 2025 PostEarnings & Low Risk High Win Rate Stock Picks - BỘ NỘI VỤ
Will Aclarion Inc. Equity Warrant stock reach Wall Street targets2025 Momentum Check & Real-Time Chart Pattern Alerts - Newser
How Aclarion Inc. stock performs in high volatility marketsTrade Exit Report & Advanced Swing Trade Entry Plans - Newser
Will Aclarion Inc. (IT20) stock outperform energy sector in 20252025 Volatility Report & AI Powered Market Trend Analysis - Newser
Aclarion, Inc. Appoints Jason Brosniak as Commercial Director for the Eastern U.S - marketscreener.com
Aclarion, Inc. (ACON) 15.7% in Intraday Trading: Appointment of Commercial Director Drives Interest - Stocks Telegraph
Aclarion appoints Jason Brosniak as commercial director, Eastern U.S. - TipRanks
Press Release: Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. - 富途牛牛
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. - The Globe and Mail
1.90%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):